Wegovy exponents did not disclose payments from Novo Nordisk
The Danish drugmaker denies any wrongdoing.
by stine løcke nielsen, translated by daniel pedersen
During a three-year period, Novo Nordisk has donated GBP 21.7m to British healthcare organizations and experts that afterward lauded the Danish drugmaker’s Wegovy (semaglutide), an obesity treatment, without disclosing such ties.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Blockbuster weight-loss drug Wegovy to be available on NHS
For subscribers
.jpg&w=384&q=75)
